Avacta AVCTF Stock
Avacta Price Chart
Avacta AVCTF Financial and Trading Overview
| Avacta stock price | 0.59 USD |
| Previous Close | 1.5 USD |
| Open | 1.5 USD |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 1.5 - 1.5 USD |
| 52 Week Range | 0.77 - 2.29 USD |
| Volume | 700 USD |
| Avg. Volume | 28 USD |
| Market Cap | 413.02M USD |
| Beta (5Y Monthly) | 1.55134 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
AVCTF Valuation Measures
| Enterprise Value | 428.5M USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 42.786907 |
| Price/Book (mrq) | 21.428572 |
| Enterprise Value/Revenue | 44.39 |
| Enterprise Value/EBITDA | -17.602 |
Trading Information
Avacta Stock Price History
| Beta (5Y Monthly) | 1.55134 |
| 52-Week Change | 94.80% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 2.29 USD |
| 52 Week Low | 0.77 USD |
| 50-Day Moving Average | 1.32 USD |
| 200-Day Moving Average | 1.35 USD |
AVCTF Share Statistics
| Avg. Volume (3 month) | 28 USD |
| Avg. Daily Volume (10-Days) | 0 USD |
| Shares Outstanding | 275.35M |
| Float | 265.13M |
| Short Ratio | N/A |
| % Held by Insiders | 34.33% |
| % Held by Institutions | 12.89% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:100 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -264.50% |
| Gross Margin | 64.15% |
| EBITDA Margin | -252.18% |
Management Effectiveness
| Return on Assets (ttm) | -22.85% |
| Return on Equity (ttm) | -132.55% |
Income Statement
| Revenue (ttm) | 9.65M USD |
| Revenue Per Share (ttm) | 0.04 USD |
| Quarterly Revenue Growth (yoy) | 190.19% |
| Gross Profit (ttm) | 6.19M USD |
| EBITDA | -24343000 USD |
| Net Income Avi to Common (ttm) | -39540000 USD |
| Diluted EPS (ttm) | -0.19 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 41.78M USD |
| Total Cash Per Share (mrq) | 0.15 USD |
| Total Debt (mrq) | 62.94M USD |
| Total Debt/Equity (mrq) | 341.38 USD |
| Current Ratio (mrq) | 0.822 |
| Book Value Per Share (mrq) | 0.07 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -16432000 USD |
| Levered Free Cash Flow (ttm) | -8628250 USD |
Profile of Avacta
| Country | United States |
| State | N/A |
| City | Wetherby |
| Address | Thorp Arch Estate |
| ZIP | LS23 7FA |
| Phone | 44 1904 217 070 |
| Website | https://www.avacta.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 120 |
Avacta Group Plc develops cancer therapies and diagnostics in the United Kingdom, France, North America, South Korea, and rest of Asia and Europe. The company operates through Diagnostics and Therapeutics segments. It develops products based on its proprietary Affimer and pre|CISION technology platforms. The company develops AVA6000, FAPa-activated doxorubicin that is in Phase I clinical trial for treating locally advanced or metastatic-selected solid tumors; AVA3996, a tumor-targeted proteasome inhibitor based on bortezomib; AVA-028-PD-L1 Affimer/ImmunoCytokines; AVA-021 - PD-L1 Affimer/LAG-3 Affimer; and TMAC platform that utilizes the proprietary pre|CISION substrate to provide for the selective release of a drug moiety by FAPa. The company has a collaboration agreement with LG Chem for developing and commercializing LR19128 PD-L1 XT; and collaboration and license agreement with Avacta and Daewoong Pharmaceutical Co. Ltd. for developing AFX-001 for solid organ transplant and graft vs host Disease, and AFX-002 for multiple sclerosis. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.
Q&A For Avacta Stock
What is a current AVCTF stock price?
Avacta AVCTF stock price today per share is 0.59 USD.
How to purchase Avacta stock?
You can buy AVCTF shares on the Other OTC exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Avacta?
The stock symbol or ticker of Avacta is AVCTF.
Which industry does the Avacta company belong to?
The Avacta industry is Biotechnology.
How many shares does Avacta have in circulation?
The max supply of Avacta shares is 390.6M.
What is Avacta Price to Earnings Ratio (PE Ratio)?
Avacta PE Ratio is now.
What was Avacta earnings per share over the trailing 12 months (TTM)?
Avacta EPS is -0.2 USD over the trailing 12 months.
Which sector does the Avacta company belong to?
The Avacta sector is Healthcare.